Zolinza approved
The Food and Drug Administration just approved zolinza for treatment of a rare form of skin cancer called cutaneous T-cell lymphoma (CTCL). In addition to CTCL, Zolinza is being investigated in other indications including myeloma, mesothelioma and a variety of other cancers that have entered phase I and II clinical trials since June 2005. It’s always good to hear about new cancer medications that scientists are working on.
